相关实验视频
Updated: Apr 12, 2026
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
1.7K
糖尿病中的心力衰竭:抗高血糖药物治疗的影响
Richard E Gilbert1, Henry Krum2
1Division of Endocrinology, St Michael's Hospital, University of Toronto, On, Canada.
Lancet (London, England)
|May 27, 2015
概括
糖尿病患者面临高心力衰竭风险. 虽然一些心力衰竭药物是有效的,但降血糖治疗对心力衰竭风险的影响需要仔细考虑,特别是新药.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病显著增加患心力衰竭的风险,并导致心力衰竭.
- 已有的心力衰竭疗法在糖尿病患者和非糖尿病患者中表现出相似的疗效.
- 密集血糖控制和各种抗高血糖剂对心血管的影响仍然不太了解.
研究的目的:
- 审查目前对糖尿病患者血糖控制和心力衰竭风险之间的关系的理解.
- 评估不同类型的抗高血糖药对心力衰竭风险的影响.
- 讨论新兴降血糖药物的心血管安全概况.
主要方法:
- 审查有关糖尿病,血糖控制和心力衰竭的现有文献.
- 对抗高血糖药物和心血管结果的临床试验数据的分析.
- 专注于特定的药物类别,包括双二-4 (DPP4) 抑制剂.
主要成果:
- 某些抗高血糖药物,如胰岛素和 thiazolidinediones,已知与留液或心力衰竭风险增加有关.
- 一个值得注意的发现是,与安慰剂相比,使用DPP4抑制剂萨克萨格利普丁增加了心力衰竭住院的风险.
- 已有的心力衰竭药物通常对糖尿病患者有效.
结论:
- 在糖尿病患者中选择抗高血糖疗法需要仔细考虑潜在的心血管风险,特别是心力衰竭.
- 需要进一步的研究,以充分阐明各种降糖药物的心血管安全性.
- 个性化治疗策略对于管理血糖控制和糖尿病心力衰竭风险至关重要.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:22Heart Failure Drugs: Diuretics
1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
01:30Heart Failure V: Medical Management
567
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
567
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K